Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase NA 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Other neoplasm 1CNS 1

Conditions

Precancerous Conditions 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Completed × pirfenidone × Clear all
NCT03177291 2025-12-05

Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
48 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00053937 2015-04-30

Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas

National Cancer Institute (NCI)

Phase 1 Completed
CNSOther neoplasm

Neurofibromatosis 1, Precancerous Conditions, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡